tetano
Editor, Senior Moderator
J Cardiothorac Vasc Anesth
. 2022 Feb 26;S1053-0770(22)00136-7.
doi: 10.1053/j.jvca.2022.02.026. Online ahead of print.
Right Ventricular Failure Manifesting in Corona Virus Disease 2019 Acute Respiratory Distress Syndrome: A Call to Transition from Venovenous Extracorporeal Membranous Oxygenation to Right Ventricular Assist Device Extracorporeal Membranous Oxygenation
Sankalp P Patel[SUP] 1 [/SUP], Brian J Solomon[SUP] 2 [/SUP], Robert D Pascotto[SUP] 2 [/SUP], Stephen E D'Orazio[SUP] 2 [/SUP], Elsy V Navas[SUP] 3 [/SUP], Robert J Cubeddu[SUP] 3 [/SUP], Gaston A Cudemus[SUP] 4 [/SUP]
Affiliations
Abstract
Often labeled the forgotten ventricle, the right ventricle's (RV) importance has been magnified over the last 2 years as providers witnessed how severe acute respiratory syndrome coronavirus 2 infection has a predilection for exacerbating RV failure. Venovenous extracorporeal membranous oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population suffering from severe COVID-19 acute respiratory distress syndrome. Concomitant early implementation of a right ventricular assist device with ECMO (RVAD-ECMO) may confer benefit in patient outcomes. The underlying mechanism of RV failure in COVID-19 has a multifactorial etiopathogenesis; nonetheless, clinical evaluation of a patient necessitating RV support remains unchanged. Herein, the authors report the case of a critically ill patient who was transitioned from a conventional VV-ECMO Medtronic Crescent cannula to RVAD-ECMO, with the insertion of the LivaNova ProtekDuo dual-lumen RVAD cannula.
Keywords: COVID-19; ProtekDuo; acute respiratory distress syndrome; extracorporeal membranous oxygenation; right ventricular assist device.
. 2022 Feb 26;S1053-0770(22)00136-7.
doi: 10.1053/j.jvca.2022.02.026. Online ahead of print.
Right Ventricular Failure Manifesting in Corona Virus Disease 2019 Acute Respiratory Distress Syndrome: A Call to Transition from Venovenous Extracorporeal Membranous Oxygenation to Right Ventricular Assist Device Extracorporeal Membranous Oxygenation
Sankalp P Patel[SUP] 1 [/SUP], Brian J Solomon[SUP] 2 [/SUP], Robert D Pascotto[SUP] 2 [/SUP], Stephen E D'Orazio[SUP] 2 [/SUP], Elsy V Navas[SUP] 3 [/SUP], Robert J Cubeddu[SUP] 3 [/SUP], Gaston A Cudemus[SUP] 4 [/SUP]
Affiliations
- PMID: 35317957
- DOI: 10.1053/j.jvca.2022.02.026
Abstract
Often labeled the forgotten ventricle, the right ventricle's (RV) importance has been magnified over the last 2 years as providers witnessed how severe acute respiratory syndrome coronavirus 2 infection has a predilection for exacerbating RV failure. Venovenous extracorporeal membranous oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population suffering from severe COVID-19 acute respiratory distress syndrome. Concomitant early implementation of a right ventricular assist device with ECMO (RVAD-ECMO) may confer benefit in patient outcomes. The underlying mechanism of RV failure in COVID-19 has a multifactorial etiopathogenesis; nonetheless, clinical evaluation of a patient necessitating RV support remains unchanged. Herein, the authors report the case of a critically ill patient who was transitioned from a conventional VV-ECMO Medtronic Crescent cannula to RVAD-ECMO, with the insertion of the LivaNova ProtekDuo dual-lumen RVAD cannula.
Keywords: COVID-19; ProtekDuo; acute respiratory distress syndrome; extracorporeal membranous oxygenation; right ventricular assist device.